+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 91 Actively Recruiting clinical trials

I

Actively Recruiting

Researchers are evaluating the use of multiparametric dynamic whole-body 68GaGa-PSMA PETCT imaging in patients newly diagnosed with hepatocellular carcinoma HCC or those with suspected refractory, residual, or recurrent HCC. The study aims to understand the diagnostic performance and impact of this imaging technique, including kinetic modeling, in detecting and assessing liver cancer. This research is sponsored by Nantes University Hospital and is categorized as a diagnostic interventional study. Participants will undergo a dynamic whole-body 68GaGa-PSMA PETCT scan designed specifically for HCC patients. This imaging involves the use of the radioactive tracer 68GaGa-PSMA-11. The study evaluates this imaging approach at baseline and over six months, focusing on diagnostic accuracy and image quality. Only one study group is involved, receiving the experimental imaging procedure. During the study, participants will have imaging assessments and evaluations of kinetic parameters at baseline and diagnostic performance at six months. Researchers will measure how well the imaging detects lesions and assess comfort during the procedure. The study will monitor participants up to six months for diagnostic outcomes and safety. Participation involves undergoing the imaging scan and follow-up assessments to evaluate the imaging methods effectiveness and acceptability.

Age: 18Years +All GendersPhase Not Applicable
2 locations
E

Actively Recruiting

This research aims to evaluate the efficacy and safety of rilzabrutinib in adults diagnosed with active Immunoglobulin G4-related disease IgG4-RD. It is a Phase 3, randomized, double-blind, placebo-controlled study that will measure the time to clinical disease flare and other important efficacy and safety outcomes over a 52-week treatment period. The study includes adult participants aged 18 and older who have a confirmed diagnosis of IgG4-RD and active disease in at least one organ. Participants will be randomly assigned to receive either rilzabrutinib tablets or a placebo, both taken orally, over a 52-week double-blind treatment period. The study also includes a screening period of 4 to 6 weeks before treatment, followed by a 2-week follow-up after the treatment phase. An optional open-label extension lasting 108 weeks is available for participants who complete the main study. The total study duration may extend up to 60 weeks for the main phases. Throughout the study, participants will attend up to 16 visits during the main treatment period and additional visits if they join the extension phase. Researchers will monitor disease activity and flare rates using clinical assessments, imaging procedures such as CT, MRI, PET, or ultrasound, laboratory tests, ECGs, and safety evaluations including adverse event monitoring. Outcomes include flare-free rates, disease activity scores, glucocorticoid use, and safety parameters, with follow-up continuing beyond the treatment phase to assess long-term effects.

Age: 18Years +All GendersPhase 3
95 locations
F

Actively Recruiting

This research aims to describe the clinical, histological, and radiological features of rare primary liver cancers. It focuses on collecting tumor and blood samples to better understand these cancers and to evaluate how well treatments used in real-world practice work, with the goal of identifying the best treatment sequences. The study serves as a foundation for future research to find new molecular and imaging biomarkers that could improve diagnosis and prognosis. The study is observational and retrospective, meaning it reviews past cases from multiple centers in France. It collects biological samples and clinical data from patients diagnosed with rare primary liver cancers after January 2018. The study evaluates treatments patients have received in clinical practice without assigning any new treatments or interventions. Participants data, including clinical characteristics, tumor biology, and imaging, will be reviewed for up to five years from diagnosis. Researchers will measure outcomes such as recurrence-free survival for patients without metastases, progression-free survival for those with metastases, and overall survival. The study includes both living patients who consent to participate and deceased patients, aiming to gather comprehensive information to support future translational studies.

Age: 18Years +All Genders
40 locations
E

Actively Recruiting

This research aims to evaluate the effects of elafibranor in adults diagnosed with Primary Biliary Cholangitis PBC who also have cirrhosis, a condition where the liver develops scarring. PBC is a slowly worsening disease that damages bile ducts in the liver, causing bile acids to build up and further harm the liver. The study focuses on whether elafibranor can better prevent worsening clinical outcomes, such as disease progression leading to liver transplant or death, compared to a placebo. It also assesses the long-term safety of elafibranor and its impact on symptoms like itching and fatigue. Participants are randomly assigned to one of two groups one group takes an 80 mg tablet of elafibranor daily, and the other takes a placebo tablet that looks the same. The tablets are taken orally each morning with or without food. This double-blind study lasts up to 3.5 years for each participant, during which the effects and safety of the study drug are closely monitored. Throughout the study, participants undergo regular assessments including physical exams, vital signs checks, blood tests, liver imaging, and questionnaires about symptoms and quality of life. These evaluations happen at baseline, then every 6 to 12 months up to the end of treatment. Researchers measure various health indicators such as liver enzyme levels, bilirubin, liver stiffness, and symptom scores. Safety is monitored by tracking adverse events and changes in laboratory and clinical findings. The primary outcome is the time participants remain free from clinical events related to disease worsening over the study period.

Age: 18Years +All GendersPhase 3
198 locations
R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
S

Actively Recruiting

This trial studies patients with decompensated cirrhosis who are at high risk of poor outcomes after hospital discharge. Researchers aim to find out if a combined therapy using human albumin and enoxaparin is safe, tolerable, and effective compared to standard medical treatment. They also want to see if this new approach costs more or less than the usual care. Participants are randomly assigned to one of two groups one group receives standard medical treatment plus the combined therapy of enoxaparin and human albumin, while the other group receives standard medical treatment alone. The study measures the safety and side effects of the combined therapy up to 90 days and evaluates disease progression and complications up to 180 days. Researchers track various organ functions, hospital readmissions, survival rates, and healthcare costs during this time. During the study, participants attend visits where tests assess liver, kidney, lung, and coagulation functions, as well as frailty and quality of life. Researchers monitor hospital admissions, complications like infections or bleeding, and use of therapeutic procedures. The main focus is on safety and tolerability of the therapy over the first 90 days, with ongoing evaluation of health outcomes and costs up to six months after starting treatment.

Age: 18Years - 80YearsAll GendersPhase 2
9 locations
S

Actively Recruiting

Researchers are evaluating the safety, tolerability, how the body processes and responds to BGB-B2033, and its preliminary antitumor activity in adults with advanced or metastatic cancers including hepatocellular carcinoma, alpha-fetoprotein-producing gastric cancer, extragonadal yolk sac tumors, non-dysgerminomas, and glypican-3-positive squamous non-small cell lung cancer. The study aims to find the recommended dose for further research when BGB-B2033 is given alone or combined with tislelizumab, with or without bevacizumab. Participants will receive BGB-B2033 through intravenous infusion either alone or combined with tislelizumab and sometimes bevacizumab. The study includes several parts dose escalation and safety expansion of BGB-B2033 alone, combination treatments to determine safe doses and recommended doses for expansion, and dose expansion in specific groups including participants with hepatocellular carcinoma in Asia and the United States. During the study, participants will have regular assessments to monitor safety, side effects, how their body processes BGB-B2033, and whether their cancer responds to treatment. Researchers will track adverse events, the best dose, overall response rates, duration of response, disease control, progression-free survival, serum drug levels, and overall survival for up to about two years. Participants will be closely monitored throughout the study period.

Age: 18Years +All GendersPhase 1Phase 2
51 locations
E

Actively Recruiting

Researchers are evaluating the glycemic efficacy, safety, and tolerability of ersodetug as an add-on treatment to standard care for patients with Tumor Hyperinsulinism Tumor HI, a condition causing low blood sugar due to hormone overproduction by certain non-removable tumors. This study focuses on patients whose hypoglycemia is not well controlled by existing therapies. It is a Phase 3, single-arm, open-label trial conducted across multiple sites in several countries. Participants will receive weekly doses of ersodetug at 9 mgkg for 8 weeks alongside their usual hypoglycemia treatments. The study has three periods an initial screening lasting up to 4 weeks, the 8-week treatment phase, and then either an end-of-study follow-up of about 20 weeks or an optional open-label extension lasting up to 3 years. The trial plans to enroll approximately 16 participants diagnosed with insulin- or IGF-producing tumors causing tumor HI. During the study, participants will be closely monitored with assessments of glucose infusion rates and other measures related to hypoglycemia control. Researchers will track changes in daily glucose infusion amounts and the time needed to stop intravenous glucose after starting ersodetug. Safety and tolerability will also be evaluated throughout the trial and follow-up periods. The total duration of participation could extend up to several years for those opting into the extension phase.

Age: 18Years +All GendersPhase 3
13 locations
P

Actively Recruiting

Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.

Age: 18Years - 80YearsAll GendersPhase 3
345 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.

Age: 18Years - 80YearsAll GendersPhase 3
359 locations

1-10 of 91

1